Satellos to Present SAT3247 Phase 1 Clinical Data in LateBreaking Poster Session at the 2025 World Muscle Society Congress

Image for article Satellos to Present SAT3247 Phase 1 Clinical Data in LateBreaking Poster Session at the 2025 World Muscle Society Congress
News Source : Financial Post

News Summary

  • Satellos Bioscience Inc. will present two scientific posters at the 30th Annual Congress of the World Muscle Society (WMS), taking place Oct. 7–11, 2025, in Vienna, Austria.
  • Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration.
  • The drug is currently in clinical development as a potential disease-modifying treatment initially for Duchenne muscular dystrophy.
TORONTO Satellos Bioscience Inc. (TSX MSCL, OTCQB MSCLF) (Satellos or the Company), a clinicalstage biotechnology company developing lifeimproving medicines to treat degenerative muscle diseases, [+7099 chars]

Must read Articles